Home / Stocks / RPRX

Royalty Pharma (RPRX, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

Royalty Pharma (RPRX, Pharmaceuticals) trades at a blended P/E of 11.2, about 16% above its historical normal valuation, with a forward growth estimate of 11.2% and a PEG of 1.00. Analysts' one-year estimates have been hit 40% of the time. Priced at its historical normal P/E of 9.7 on the same blended earnings, the 2026-09-18 close of $58.41 corresponds to about $50.20 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
11.2
Normal P/E
9.7
PEG
1.00
Fwd growth
11.2%
Div yield
1.6%
RSI (14)
39.0
Neutral
Technical context
  • Price $57.65 at the 2026-09-23 close, 4.6% below the 20-day average ($60.46) and 2.7% below the 50-day ($59.26).
  • RSI (14) at 39.0.
  • 52-week range $34.24 to $63.96: the price is 9.9% below the high and 68.4% above the low.

The Street vs SeerForecast

Wall Street's mean price target for RPRX is $65.12 across 8 analysts, 13.0% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from trading above fair value (2026-07-31) to fairly valued (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 11.6 to 11.2 between 2026-07-31 and 2026-09-21, against a normal P/E of 9.7, with 3 rating changes over 18 recorded weeks.2026-07-31: P/E 11.6, Trading above fair value (recalculated)2026-08-03: P/E 11.5, Fairly valued2026-08-07: P/E 11.5, Fairly valued (recalculated)2026-08-10: P/E 11.1, Fairly valued2026-08-14: P/E 11.1, Fairly valued (recalculated)2026-08-17: P/E 11.4, Fairly valued2026-08-21: P/E 11.4, Fairly valued (recalculated)2026-08-24: P/E 11.9, Trading above fair value2026-08-27: P/E 11.9, Trading above fair value (recalculated)2026-08-28: P/E 11.9, Trading above fair value (recalculated)2026-08-30: P/E 11.9, Trading above fair value (recalculated)2026-08-31: P/E 11.8, Trading above fair value2026-09-05: P/E 11.8, Trading above fair value (recalculated)2026-09-07: P/E 12.4, Trading above fair value2026-09-12: P/E 12.4, Trading above fair value (recalculated)2026-09-14: P/E 11.3, Fairly valued2026-09-19: P/E 11.3, Fairly valued (recalculated)2026-09-21: P/E 11.2, Fairly valued10.011.012.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 9.7
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 11.6+20%Trading above fair value
2026-08-03P/E 11.5+19%Fairly valued
2026-08-10P/E 11.1+15%Fairly valued
2026-08-24P/E 11.9+23%Trading above fair value
2026-09-07P/E 12.4+28%Trading above fair value
2026-09-14P/E 11.3+17%Fairly valued
2026-09-21P/E 11.2+16%Fairly valued ← now

Frequently asked questions

Is Royalty Pharma stock overvalued?

At a blended P/E of 11.2 versus its historical normal P/E of 9.7, Royalty Pharma trades about 16% above its typical valuation, with a PEG of 1.00 on 11.2% forward growth. tickerseer currently rates it fairly valued.

What is Royalty Pharma's fair value and PEG?

Royalty Pharma trades at a blended P/E of 11.2 against a historical normal P/E of 9.7, a PEG of 1.00, and a forward growth estimate of 11.2%. Priced at its historical normal P/E of 9.7 on the same blended earnings, the 2026-09-18 close of $58.41 corresponds to about $50.20 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Royalty Pharma changed?

tickerseer's rating moved from trading above fair value (2026-07-31) to fairly valued (2026-09-21).

What is the analyst price target for Royalty Pharma?

The mean Wall Street price target for Royalty Pharma is $65.12 across 8 analysts, 13.0% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track RPRX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.